3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Sarcoma
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Breast Neoplasms
4
Sarcoma, Ewing
3
Neoplasms
3
Insulin-Like Growth Factor I, Resistance To
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Lymphoma
2
Colonic Neoplasms
2
Carcinoid Tumor
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pathologic Complete Response
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Carboplatin
340
Cisplatin
238
Paclitaxel
203
Radiotherapy
195
Pemetrexed
187
Docetaxel
169
Gemcitabine
157
pembrolizumab
141
Erlotinib Hydrochloride
107
Etoposide
99
Magnetic Resonance Spectroscopy
93
Bevacizumab
91
Specimen Handling
76
Nivolumab
73
Radiosurgery
72
durvalumab
69
Vinorelbine
54
osimertinib
53
Gefitinib
49
Drug Therapy
49
atezolizumab
42
Irinotecan
42
Radiation
40
Topotecan
39
Biopsy
39
Standard of Care
38
Cyclophosphamide
38
Cetuximab
35
Blood Specimen Collection
33
Taxes
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lung Neoplasms
×
ganitumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts